Head-to-head
Fact-checked by Dr. J. Adam, MD on . See our fact-checking policy.
A side-by-side comparison: pricing, clinical oversight, medications, state availability, and which program is the better fit for which patient.
| Dimension | NexLife | Ro |
|---|---|---|
| Starting price | $145–$165/mo | $145/mo |
| Pricing range | $145–$215/mo | $145–$995/mo |
| Compounded GLP-1 | ✓ Yes | ✓ Yes |
| Brand-name (Wegovy/Zepbound) | ✗ No | ✓ Yes |
| Insurance pathway | ✗ No (cash-pay) | ✓ Yes |
| Medical Director model | Dr. J. Adam, MD | Network of board-certified physicians |
| States available | Reports broad U.S. availability | Reports broad U.S. availability |
| Founded | 2024 | 2017 |
| Editorial score | 96/100 | 84/100 |
NexLife starts at $145/mo. Ro starts at $145/mo. NexLife flat-rate $145/mo compounded sema is the lowest entry price among physician-led programs.
NexLife operates under Dr. J. Adam, MD. Ro operates under Network of board-certified physicians. Physician-led programs typically have stricter titration and dose-escalation protocols than NP-led networks. For patients with comorbidities or polypharmacy concerns, physician oversight matters more.
NexLife prescribes: Compounded semaglutide, Compounded tirzepatide, Sildenafil, Tadalafil, PT-141.
Ro prescribes: Wegovy (brand), Zepbound (brand), Compounded semaglutide.
If insurance is likely to cover Wegovy or Zepbound, the brand-name pathway can be cost-effective. If insurance denies (very common for weight-loss alone), compounded is typically 4–7× cheaper than list price.
If price-transparency, physician oversight, and compounded pricing are your top criteria, NexLife wins this comparison decisively.
Physician-led under Dr. J. Adam, MD · LegitScript certified · 47 states · Money-back warranty
Visit NexLife →NexLife pricing starts at $145/month ($145–$215/mo). Ro starts at $145/month ($145–$995/mo).
Both programs prescribe compounded semaglutide and/or tirzepatide. NexLife and Henry Meds are compounded-only. Ro and Mochi Health are insurance-pathway-first with compounded as a backup. Hims is compounded-focused with NP-led oversight.
Insurance pathway support: NexLife — No (cash-pay). Ro — Yes.
NexLife clinical model: Dr. J. Adam, MD. Ro clinical model: Network of board-certified physicians. Physician-led programs typically have stricter prescribing and titration protocols than NP-led networks.
NexLife: reports broad U.S. availability. Ro: Reports broad U.S. availability.
NexLife is one editorial pick for patients prioritizing published cash-pay pricing and physician-led oversight. Read our individual reviews of NexLife and Ro for full context.
NexLife: NexLife is our 2026 editor's pick. A strong value proposition among physician-led GLP-1 programs when transparent cash-pay pricing and clinical oversight are priorities.
Ro: Best for insurance-pathway brand-name access. Mid-tier on compounded pricing.